| Opportunity ID: |
293155 |
| Opportunity Number: |
NOT-HL-17-499 |
| Opportunity Title: |
Notice of Intent to Publish a Funding Opportunity Announcement to Support Competitive Revision Applications in Regenerative Medicine Innovation Projects (RMIP) (R41/R42) |
| Opportunity Category: |
Discretionary |
| Opportunity Category Explanation: |
|
| Funding Instrument Type: |
Grant |
| Category of Funding Activity: |
Health |
| Category Explanation: |
|
| CFDA Number(s): |
93.837 |
| Eligible Applicants: |
State governments
County governments
City or township governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: |
|
| Agency Code: |
HHS-NIH11 |
| Agency Name: |
Department of Health and Human Services
National Institutes of Health |
| Posted Date: |
Apr 12, 2017 |
| Last Updated Date: |
Apr 12, 2017 |
| Estimated Synopsis Post Date: |
May 01, 2017 |
| Fiscal Year: |
2017 |
| Award Ceiling: |
|
| Award Floor: |
|
| Estimated Total Program Funding: |
|
| Expected Number of Awards: |
|
| Description: |
?The National Institutes of Health (NIH) and participating NIH Institutes and Centers (ICs) and the U.S. Food and Drug Administration (FDA) intend to publish a Funding Opportunity Announcement (FOA) for competitive revisions that will support clinical research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. The planned FOA, known as the Regenerative Medicine Innovation Project (RMIP),will support revision projects that utilize rigorous science and reproducible methods to establish proof of concept and evidence base for clinical applications. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of product manufacturing, quality, safety, or effectiveness. In order to fulfill the mandate of advancing the field of RM more broadly, applicants will propose solutions to widely recognized issues in the development of safe and effective regenerative medicine products. |
| Version: |
Forecast 1 |
